Novo Nordisk A/S Closed Now

Novo Nordisk A/S is a Danish multinational pharmaceutical company and a global leader in diabetes care, obesity treatments, and rare disease therapies. Founded in 1923, the company has nearly a century of expertise in developing insulin and other diabetes medicines, and it continues to shape the future of metabolic and chronic disease management. In recent years, Novo Nordisk has gained worldwide recognition for its groundbreaking GLP-1 therapies, such as Ozempic and Wegovy, used for diabetes and weight management.

Mission and Vision

• Mission: To drive change to defeat diabetes and other serious chronic diseases.

• Vision: To improve the lives of patients worldwide by pioneering innovative medicines and expanding access to care.

Products and Services

• Diabetes Care: Insulin analogs, GLP-1 receptor agonists (Ozempic, Rybelsus), and insulin delivery devices.

• Obesity Treatments: Wegovy and Saxenda, leading medicines for weight management.

• Rare Diseases: Therapies for hemophilia, growth disorders, and rare endocrine diseases.

• Cardiovascular & Chronic Disease Pipeline: Expanding GLP-1 therapies to cardiovascular and kidney health.

• Digital Health & Devices: Advanced insulin pens, connected devices, and patient support programs.

Growth and Innovation
Novo Nordisk has pioneered insulin production since its founding and continues to innovate in diabetes management. Its GLP-1 drug class has transformed treatment for type 2 diabetes and obesity, with Ozempic and Wegovy becoming blockbuster therapies. The company is heavily investing in next-generation obesity drugs, gene therapy, and digital health solutions to address chronic diseases globally.

Global Impact
With a presence in more than 80 countries, Novo Nordisk medicines are used by over 40 million patients worldwide. The company plays a central role in tackling the global diabetes and obesity epidemic. Novo Nordisk also invests in sustainability and health equity, aiming for zero environmental impact by 2045 and improving access to insulin in low- and middle-income countries.